Researchers to Present New Data on Appili Therapeutics Infectious Disease Programs at the 2019 Military Health System Research Symposium

ATI-1701 data demonstrate safety and efficacy of the Francisella tularensis vaccine candidate in preclinical studies and support ongoing accelerated development under FDA’s ‘Animal Rule’

ATI-1503 research identifies a potential Gram-negative antibiotic candidate for clinical development from Appili’s negamycin program

HALIFAX, Nova Scotia--()--Today, Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, will present updated data on the company’s ATI-1701 and ATI-1503 programs at the Military Health System Research Symposium (MHSRS). The conference is currently being held from August 19-22 at the Gaylord Palms Resort and Convention Centre in Kissimmee, Florida.

“Through ongoing partnerships with federal agencies, including the U.S. Department of Defense (DOD), we have been able to advance our anti-infective programs that address urgent infectious disease-related needs in military and civilian healthcare settings,” said Kevin Sullivan, CEO of Appili Therapeutics. “From transformational programs that address the most threatening multidrug resistant bacteria to preparing medical countermeasures for potential bioterrorism threats, I am very proud of our team’s work to advance our tularemia vaccine research and gram-negative antibiotic programs. There remains a tremendous unmet medical need to develop programs that addresses the significant gaps in the anti-infective landscape, and we are excited to share our progress with our DOD counterparts at the MHSRS. Although these results are preliminary, they are encouraging and headed in the right direction.”

​Presentation details include:

Title: ATI-1701, a live attenuated Francisella tularensis vaccine for the prevention of pneumonic tularemia in the Warfighter
Session: Innovative Countermeasures and Diagnostics for Emerging Infectious Diseases
Date: Tuesday, August 20, 2019
Time: 10:00 a.m. – 12:00 p.m.
Location: Exhibit Hall, Section Florida DEF

Title: ATI-1503, a Novel Negamycin Analogue for the Treatment of Multi Drug Resistant Gram-negative Infection
Session: Non-vaccine Approaches to Prevent or Treat Militarily Related Infections
Date: Tuesday, August 20, 2019
Time: 10:00 a.m. – 12:00 p.m.
Location: Exhibit Hall, Section Florida DEF

About the Military Health System Research Symposium (MHSRS)

The Military Health System Research Symposium (MHSRS) is the U.S. Department of Defense’s premier scientific meeting. It provides a venue for presenting new scientific knowledge resulting from military-unique medical research and development. The MHSRS is the principal military or civilian meeting that focuses specifically on the unique medical needs of the Warfighter.

The MHSRS provides a collaborative setting for the exchange of information between military providers with deployment experience, research and academic scientists, international partners, and industry on research and related health care initiatives. The theme for the 2019 MHSRS is Research for Readiness. The scientific presentations will focus on four critical areas – Warfighter Medical Readiness, Expeditionary Medicine, Warfighter Performance, and Return to Duty.

About Appili Therapeutics

Appili Therapeutics, Inc. was founded to advance the global fight against infectious disease by matching clearly-defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors, and society face in this challenging disease space. Appili has built a pipeline of assets designed to address a broad range of significant unmet medical needs in the infectious disease landscape. This diverse pipeline aims to address some of the most urgent threats in global public health. Via an in-licensing program, Appili acquired the rights to ATI-1701, a vaccine for tularemia, being developed to mitigate the risks of a very serious biological weapons threat. ATI-1503 is a drug discovery program aimed at generating negamycin analogue candidates, which are a novel class of antibiotics with broad-spectrum activity against Gram-negative superbugs. ATI-1501 employs Appili’s proprietary, taste-masked, oral-suspension technology with metronidazole for the growing number of patients with difficulty swallowing. Headquartered in Halifax, Nova Scotia, with offices in Mississauga, Ontario, Appili is pursuing worldwide opportunities in collaboration with science and industry commercial partners, governments and government agencies. For more information, visit www.AppiliTherapeutics.com.

This news release contains “forward-looking statements” which reflect the current expectations of the Company’s management future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company’s proposed development plans with respect to ATI-1503 and the proposed use of proceeds from the PRMRP grant. Wherever possible, words such as “may “, “would “, “could “, “should”, “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions including with respect to the ability of the Company to adequately fund and implement its development plans and business strategy. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements including, without limitation, those listed in the final prospectus of the Company dated June 12, 2019 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Contacts

Media Relations:
Andrea Cohen, Sam Brown Inc.
T: 917-209-7163
E: andreacohen@sambrown.com

Investor Relations:
Kimberly Stephens, CFO
Appili Therapeutics
E: Info@AppiliTherapeutics.com

$Cashtags

Contacts

Media Relations:
Andrea Cohen, Sam Brown Inc.
T: 917-209-7163
E: andreacohen@sambrown.com

Investor Relations:
Kimberly Stephens, CFO
Appili Therapeutics
E: Info@AppiliTherapeutics.com